PredxBio (formerly SpIntellx) is a Pittsburgh-based scaling-stage technology company specializing in explainable AI-powered spatial analytics software for spatial biology, primarily focused on immuno-oncology to predict disease progression, accelerate drug discovery, optimize clinical trials, and personalize cancer therapies.[1][2][3] The company builds the SpaceIQ™ platform, which integrates brightfield, spatial proteomics, and transcriptomics datasets to provide high-resolution views of the tumor microenvironment (TME), enabling insights into cellular interactions, immune architecture, therapeutic responses, and resistance mechanisms.[4] It serves pharma partners, clinicians, researchers, and biopharma companies in cancer drug development, solving the challenges of high costs and long timelines in immunotherapy by identifying biomarkers, novel targets, and responsive patient sub-populations with greater precision; early paying customers have already engaged for treatment response assessments.[1][4]
Growth momentum includes seed financing closed in 2018, a 2023 rebranding to align with platform evolution, and recent 2024-2025 partnerships with PictorLabs for AI-powered virtual staining and Sirona Dx for multi-omics integration, plus a major SpaceIQ™ enhancement launch ahead of AACR 2025.[2][4] With around 15 employees and estimated $2.3M annual revenue, PredxBio demonstrates steady scaling in computational pathology.[5]
SpIntellx was co-founded in 2018 in Pittsburgh, PA, by D. Lansing Taylor (Chairman), S. Chakra Chennubhotla (President), Jeffrey L. Fine, and Michael J. Becich, leveraging licenses from the University of Pittsburgh to apply proprietary AI for spatial analytics in digital pathology.[2] The idea emerged from advancing computational tools like HistoMapr™ (for automatic region classification in H&E and IHC slides to boost pathologist efficiency) and TumorMapr™ (for spatial interaction analysis in multiplexed fluorescence images to predict outcomes and support precision medicine).[2] Early traction came via seed financing led by Newlin Investment Company, initial validation studies, and a focus on pathologists, cancer biopharma, and drug developers.[2]
Pivotal moments include the 2023 rebranding to PredxBio under CEO B. Dusty Majumdar, reflecting matured capabilities in unbiased spatial analytics and explainable AI (xAI) for immuno-oncology, with the platform now empowering drug discovery and trials.[1][3] This evolution built on completed pharma engagements and positioned the company for broader impact in bending survival curves for immunotherapy patients.[1]
PredxBio stands out in spatial biology through these key strengths:
PredxBio rides the spatial biology wave, fueled by advances in multi-omics imaging and AI to decode complex TME heterogeneity in cancer, where traditional pathology falls short in predicting immunotherapy responses.[1][4] Timing is ideal amid rising immuno-oncology investments, as pharma seeks cost reductions (e.g., shorter trials via precise sub-populations) amid failures in heterogeneous tumors.[1] Market forces like AACR spotlights, AI-virtual staining synergies, and multi-omics demand favor PredxBio's xAI edge, influencing the ecosystem by enabling real-world evidence for prognostics, companion diagnostics, and personalized medicine—potentially lowering drug development timelines and improving patient outcomes.[2][4]
PredxBio is poised for accelerated growth through SpaceIQ™ expansions, deeper pharma integrations, and 2025 AACR momentum, potentially capturing more market share in a spatial omics sector projected to boom with AI advancements.[4] Trends like unified multi-modal data analytics and explainable models will shape its path, evolving its influence from niche pathology tools to core enabler in precision oncology ecosystems. As the rebranded successor to SpIntellx's foundational AI-spatial intelligence, it remains uniquely positioned to transform cancer survival curves.[1][3]
SpIntellx has raised $50K in total across 1 funding round.
SpIntellx's investors include Innovation Works.
SpIntellx has raised $50K across 1 funding round. Most recently, it raised $50K Seed in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $50K Seed | Innovation Works |
